Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Scand J Gastroenterol ; 59(5): 543-546, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38343268

RESUMO

The basic principle for the treatment of idiopathic diarrhoea (functional diarrhoea K59.1) is to delay transit through the gut in order to promote the absorption of electrolytes and water. Under mild conditions, bulking agents may suffice. With increasing severity, antidiarrhoeal pharmaceuticals may be added in a stepwise manner. In diarrhoea of unknown aetiology, peripherally-acting opioid receptor agonists, such as loperamide, are first-line treatment and forms the pharmaceutical basis of antidiarrheal treatment. As second-line treatment opium drops have an approved indication for severe diarrhoea when other treatment options fail. Beyond this, various treatment options are built on experience with more advanced treatments using clonidine, octreotide, as well as GLP-1 and GLP-2 analogs which require specialist knowledge the field.


Chronic diarrhoea without an established cause is common.There are a small number of clinical trials, often with a limited number of patients or healthy volunteers.Treatment is often carried out on a trial-and-error basis, with considerable variation in the choice of treatment.There is a paucity of guidelines, and there is a gap in knowledge concerning treatment goals, such as the frequency, consistency and form of stool.The stepwise approach to the treatment of chronic idiopathic diarrhoea described in this article is based on clinical knowledge and experience.


Assuntos
Antidiarreicos , Diarreia , Humanos , Diarreia/tratamento farmacológico , Diarreia/etiologia , Antidiarreicos/uso terapêutico , Loperamida/uso terapêutico , Octreotida/uso terapêutico , Clonidina/uso terapêutico , Clonidina/análogos & derivados
2.
BMC Cancer ; 20(1): 466, 2020 May 24.
Artigo em Inglês | MEDLINE | ID: mdl-32448245

RESUMO

BACKGROUND: There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally, the aim of these treatments has been to reduce the tumor load; referred to as objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without a reduction in total tumor load; termed as stable disease (SD). We wanted to investigate whether achieving OR compared to obtaining SD predicted a longer time to progression (TTP) in patients with neuroendocrine tumors (WHO Grade 1 and 2) treated with peptide receptor radionuclide therapy, chemotherapy or molecular targeted therapy. METHODS: Patients treated with either peptide receptor radionuclide therapy (PRRT) with 177Lutetium-DOTA-octreotate, the chemotherapy combination streptozotocin/5-fluorouracil or everolimus were retrospectively assessed to evaluate the effect of the treatments on disease progression. We analyzed the TTP for patients for each treatment modality and compared the TTP between those who achieved OR and those who achieved SD. RESULTS: Altogether 56 patients treated with PRRT, 32 treated with streptozotocin/5-fluorouracil and 52 treated with everolimus were included in the analyses. The median TTP for those treated with PRRT and achieving OR was 31 months, the TTP for those achieving SD was 43 months (p = 0,2). For patients treated with streptozotocin/5-fluorouracil the results were: OR: 18 months, SD: 23 months (p = 0,9) and for those treated with everolimus; OR: 9 months, SD: 20 months (p = 0,5), respectively. We found no differences between patients achieving OR compared to SD regarding age, sex, stage, primary tumor location, Ki-67% or ongoing treatment with somatostatin analogues. CONCLUSIONS: We found no treatment benefit with regard to TTP for our patients that experienced OR compared to those who achieved SD.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Tumores Neuroendócrinos/patologia , Octreotida/análogos & derivados , Compostos Organometálicos/administração & dosagem , Compostos Radiofarmacêuticos/administração & dosagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Terapia Combinada , Progressão da Doença , Everolimo/administração & dosagem , Feminino , Fluoruracila/administração & dosagem , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Tumores Neuroendócrinos/terapia , Octreotida/administração & dosagem , Octreotida/metabolismo , Compostos Organometálicos/metabolismo , Prognóstico , Compostos Radiofarmacêuticos/metabolismo , Receptores de Peptídeos/metabolismo , Estudos Retrospectivos , Estreptozocina/administração & dosagem , Taxa de Sobrevida , Fatores de Tempo
3.
Neuroradiology ; 59(2): 105-126, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28255902

RESUMO

Neurologic complications are common after hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) and affect 30-60% of transplant recipients. The aim of this article is to provide a practical imaging approach based on the timeline and etiology of CNS abnormalities, and neurologic complications related to transplantation of specific organs. The lesions will be classified based upon the interval from HSCT procedure: pre-engraftment period <30 days, early post-engraftment period 30-100 days, late post-engraftment period >100 days, and the interval from SOT procedure: postoperative phase 1-4 weeks, early posttransplant syndromes 1-6 months, late posttransplant syndromes >6 months. Further differentiation will be based on etiology: infections, drug toxicity, metabolic derangements, cerebrovascular complications, and posttransplantation malignancies. In addition, differentiation will be based on complications specific to the type of transplantation: allogeneic and autologous hematopoietic stem cells (HSC), heart, lung, kidney, pancreas, and liver. Thus, in this article we emphasize the strategic role of neuroradiology in the diagnosis and response to treatment by utilizing a methodical approach in the work up of patients with neurologic complications after transplantation.


Assuntos
Doenças do Sistema Nervoso Central/diagnóstico por imagem , Transplante de Células-Tronco Hematopoéticas , Transplante de Órgãos , Complicações Pós-Operatórias/diagnóstico por imagem , Humanos
4.
Hepatology ; 62(4): 1249-59, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25855031

RESUMO

UNLABELLED: Cholangiocytes express antigen-presenting molecules, but it has been unclear whether they can present antigens. Natural killer T (NKT) cells respond to lipid antigens presented by the major histocompatibility complex class I-like molecule CD1d and are abundant in the liver. We investigated whether cholangiocytes express CD1d and present lipid antigens to NKT cells and how CD1d expression varies in healthy and diseased bile ducts. Murine and human cholangiocyte cell lines as well as human primary cholangiocytes expressed CD1d as determined by flow cytometry and western blotting. Murine cholangiocyte cell lines were able to present both exogenous and endogenous lipid antigens to invariant and noninvariant NKT cell hybridomas and primary NKT cells in a CD1d-dependent manner. A human cholangiocyte cell line, cholangiocarcinoma cell lines, and human primary cholangiocytes also presented exogenous CD1d-restricted antigens to invariant NKT cell clones. CD1d expression was down-regulated in the biliary epithelium of patients with late primary sclerosing cholangitis, primary biliary cirrhosis, and alcoholic cirrhosis compared to healthy controls. CONCLUSIONS: Cholangiocytes express CD1d and present antigens to NKT cells and CD1d expression is down-regulated in diseased biliary epithelium, findings which show that the biliary epithelium can activate an important lymphocyte subset of the liver. This is a potentially important immune pathway in the biliary system, which may be capable of regulating inflammation in the context of biliary disease.


Assuntos
Ductos Biliares/imunologia , Ativação Linfocitária , Células T Matadoras Naturais/imunologia , Animais , Antígenos CD1d/fisiologia , Células Cultivadas , Células Epiteliais/imunologia , Epitélio/imunologia , Humanos , Camundongos , Camundongos Endogâmicos C57BL
5.
Arterioscler Thromb Vasc Biol ; 33(2): e47-55, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23162017

RESUMO

OBJECTIVE: Interleukin (IL)-33 is a nuclear protein that is released from stressed or damaged cells to act as an alarmin. We investigated the effects of IL-33 on endothelial cells, using the prototype IL-1 family member, IL-1ß, as a reference. METHODS AND RESULTS: Human umbilical vein endothelial cells were stimulated with IL-33 or IL-1ß, showing highly similar phosphorylation of signaling molecules, induction of adhesion molecules, and transcription profiles. However, intradermally injected IL-33 elicited significantly less proinflammatory endothelial activation when compared with IL-1ß and led us to observe that quiescent endothelial cells (ppRb(low)p27(high)) were strikingly resistant to IL-33. Accordingly, the IL-33 receptor was preferentially expressed in nonquiescent cells of low-density cultures, corresponding to selective induction of adhesion molecules and chemokines. Multiparameter phosphoflow cytometry confirmed that signaling driven by IL-33 was stronger in nonquiescent cells. Manipulation of nuclear IL-33 expression by siRNA or adenoviral transduction revealed no functional link between nuclear, endogenous IL-33, and exogenous IL-33 responsiveness. CONCLUSIONS: In contrast to other inflammatory cytokines, IL-33 selectively targets nonquiescent endothelial cells. By this novel concept, quiescent cells may remain nonresponsive to a proinflammatory stimulus that concomitantly triggers a powerful response in cells that have been released from contact inhibition.


Assuntos
Proliferação de Células , Dermatite/imunologia , Células Endoteliais/imunologia , Mediadores da Inflamação/metabolismo , Interleucinas/metabolismo , Pele/irrigação sanguínea , Adenoviridae/genética , Animais , Biópsia , Células Cultivadas , Senescência Celular , Inibidor de Quinase Dependente de Ciclina p27/metabolismo , Dermatite/patologia , Selectina E/metabolismo , Células Endoteliais/patologia , Feminino , Citometria de Fluxo , Vetores Genéticos , Células Endoteliais da Veia Umbilical Humana/imunologia , Humanos , Interleucina-1beta/metabolismo , Interleucina-33 , Interleucinas/genética , Proteínas Quinases JNK Ativadas por Mitógeno/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , NF-kappa B/metabolismo , Neovascularização Fisiológica , Fosforilação , Interferência de RNA , Receptores de Interleucina/metabolismo , Proteína do Retinoblastoma/metabolismo , Transdução de Sinais , Transcrição Gênica , Transdução Genética , Transfecção , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
6.
Scand J Gastroenterol ; 49(4): 492-500, 2014 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-24597781

RESUMO

OBJECTIVE: To use information from the referral letters to assess the appropriateness of colonoscopies in a primary open-access referral center, according to the criteria from the European Panel on the Appropriateness of Gastrointestinal Endoscopy (EPAGE) II, and to compare with the first EPAGE guidelines. Second, to evaluate how the appropriateness and other patient- or doctor-related factors affected the diagnostic yield (DY). MATERIAL AND METHODS: A set of variables; symptoms, referring physician and final diagnosis, for 323 referrals accepted for colonoscopy were recorded prospectively and later on assessed using the EPAGE and EPAGE II criteria, respectively. Patients with incomplete visualization of the entire colon or colonoscopic findings as indication were excluded. RESULTS: EPAGE and EPAGE II criteria were applicable in 287 (95.3%) and 295 (98.0%) referrals, respectively. A total of 166 (57.8%) patients were considered appropriate by EPAGE and 240 (81.4%) patients were considered appropriate by EPAGE II. DY for appropriate versus uncertain/inappropriate referrals was 34.9% versus 17.4% for EPAGE (odds ratio [OR] = 2.5, 95% confidence interval [CI]: 1.8-4.4, p = 0.003) and 31.3% versus 10.9% for EPAGE II (OR = 3.5, 95% CI: 1.4-8.9, p = 0.007). Sensitivity was higher for EPAGE II (92.6% vs. 73.4%). According to EPAGE II, 68 (23.1%) patients were referred due to lesions identified on other diagnostic procedures, producing a DY of 39.7%. In this group, 70% presented symptoms appropriate for a primary referral to colonoscopy. CONCLUSIONS: The majority of colonoscopies were found appropriate by EPAGE II. There was a clear association between high appropriateness of the indication and a high DY. EPAGE II is a guideline-improvement that may be useful for both referring physicians and gastroenterologists when considering referrals.


Assuntos
Colonoscopia/normas , Seleção de Pacientes , Guias de Prática Clínica como Assunto , Controle de Qualidade , Europa (Continente) , Humanos , Guias de Prática Clínica como Assunto/normas , Estudos Prospectivos
7.
Am J Pathol ; 181(3): 1099-111, 2012 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22809957

RESUMO

The molecular mechanisms that drive expression of the alarmin interleukin-33 (IL-33) in endothelial cells are unknown. Because nuclear IL-33 is a marker of endothelial cell quiescence (corroborated in this study by coexpression of cyclin-dependent kinase inhibitor p27(Kip1)), we hypothesized that Notch signaling might be involved in regulating IL-33 expression. Activation of Notch1 by immobilized Notch ligands was sufficient to induce nuclear IL-33 expression in cultured endothelial cells. Conversely, IL-33 expression was inhibited by the γ-secretase inhibitor DAPT or by inhibiting the function of Dll4, Jagged1, Notch1, or the canonical Notch transcription factor RBP-Jκ. Insensitivity to cycloheximide indicated that IL-33 was a direct target of Notch signaling, well in line with the identification of several conserved RBP-Jκ binding sites in the IL33 gene. The in vivo expression of Dll4 but not of Jagged1 was well correlated with expression of IL-33 in quiescent vessels, and subcutaneous injection of DAPT in healthy skin reduced IL-33 expression, indicating that Notch signaling was involved. On the other hand, loss of IL-33 during angiogenesis occurred despite sustained Dll4 and Notch1 expression, suggesting that other signals may override the IL-33-driving signal in this context. Taken together, our data demonstrate that endothelial nuclear IL-33 is induced by Notch and that Dll4 may be the dominant ligand responsible for this signaling in vivo.


Assuntos
Células Endoteliais/citologia , Células Endoteliais/metabolismo , Interleucinas/metabolismo , Receptor Notch1/metabolismo , Proteínas Adaptadoras de Transdução de Sinal , Secretases da Proteína Precursora do Amiloide/antagonistas & inibidores , Secretases da Proteína Precursora do Amiloide/metabolismo , Animais , Sítios de Ligação , Biomarcadores/metabolismo , Proteínas de Ligação ao Cálcio/metabolismo , Núcleo Celular/efeitos dos fármacos , Núcleo Celular/metabolismo , Dipeptídeos/farmacologia , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/genética , Células Endoteliais/efeitos dos fármacos , Células Endoteliais/enzimologia , Feminino , Loci Gênicos/genética , Genoma Humano/genética , Células Endoteliais da Veia Umbilical Humana/metabolismo , Humanos , Proteína de Ligação a Sequências Sinal de Recombinação J de Imunoglobina/metabolismo , Peptídeos e Proteínas de Sinalização Intercelular/metabolismo , Interleucina-33 , Interleucinas/genética , Proteína Jagged-1 , Masculino , Proteínas de Membrana/metabolismo , Neovascularização Fisiológica/efeitos dos fármacos , Neovascularização Fisiológica/genética , Ligação Proteica/efeitos dos fármacos , Ratos , Ratos Wistar , Receptor Notch1/antagonistas & inibidores , Proteínas Serrate-Jagged , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/genética , Cicatrização/efeitos dos fármacos
8.
Am J Pathol ; 177(6): 2804-15, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21037074

RESUMO

Interleukin-33 (IL-33) is a novel member of the interleukin-1 family that induces mucosal pathology in vivo and may drive fibrosis development and angiogenesis. To address its potential role in inflammatory bowel disease, we explored its tissue expression in biopsy specimens from untreated ulcerative colitis patients, observing a 2.6-fold up-regulation of IL-33 mRNA levels, compared to controls. Immunohistochemical analyses of surgical specimens showed that a prominent source of IL-33 in ulcerative colitis lesions were ulceration-associated myofibroblasts that co-expressed the fibroblast marker heat shock protein 47, platelet-derived growth factor receptor (PDGFR)ß, and, in part, the myofibroblast marker α-smooth muscle actin (SMA). In contrast, IL-33-positive myofibroblasts were almost absent near the deep fissures seen in Crohn's disease. A screen of known and putative activators of IL-33 in cultured fibroblasts revealed that the Toll-like receptor-3 agonist poly (I:C) was among the strongest inducers of IL-33 and that it synergized with transforming growth factor-ß, a combination also known to boost myofibroblast differentiation. Experimental wound healing in rat skin revealed that the de novo induction of IL-33 in pericytes and the possible activation of scattered, tissue-resident IL-33(+)PDGFRß(+)αSMA(-) fibroblast-like cells were early events that preceded the later appearance of IL-33(+)PDGFRß(+)αSMA(+) cells. In conclusion, our data point to a novel role for IL-33 in mucosal healing and wound repair and to an interesting difference between ulcerative colitis and Crohn's disease.


Assuntos
Colite Ulcerativa/genética , Doenças Inflamatórias Intestinais/genética , Interleucinas/genética , Miofibroblastos/metabolismo , Animais , Biópsia , Estudos de Casos e Controles , Células Cultivadas , Colite Ulcerativa/metabolismo , Colite Ulcerativa/patologia , Colo/efeitos dos fármacos , Colo/metabolismo , Colo/patologia , Doença de Crohn/genética , Doença de Crohn/metabolismo , Doença de Crohn/patologia , Expressão Gênica/efeitos dos fármacos , Humanos , Doenças Inflamatórias Intestinais/metabolismo , Doenças Inflamatórias Intestinais/patologia , Interleucina-33 , Interleucinas/metabolismo , Miofibroblastos/efeitos dos fármacos , Miofibroblastos/patologia , Poli I-C/farmacologia , Ratos , Receptor 3 Toll-Like/agonistas , Fator de Crescimento Transformador beta/farmacologia , Cicatrização/genética , Cicatrização/fisiologia
9.
Scand J Gastroenterol ; 46(9): 1081-91, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21619483

RESUMO

OBJECTIVE: The present population based adult cohort was part of a new prospective study of patients with inflammatory bowel disease (IBD) in South-Eastern Norway, the Inflammatory Bowel South-Eastern Norway II study, investigating disease characteristics in an attempt to improve our knowledge regarding factors related to early clinical phenotype and disease activity. MATERIAL AND METHODS: Patients suspected to have IBD on the basis of predefined symptoms, including abdominal pain, diarrhea, and/or blood in stool for more than 10 days were examined at the local hospital. Colonoscopy with biopsies was performed and blood and stool samples were taken. RESULTS: In ulcerative colitis (UC) patients, the median Simple Clinical Colitis Activity Index (SCCAI) was 4 (range 0-10) in mild and 6 (range 0-14) in patients with moderate or severe endoscopic activity of inflammation (p = 0.002). The calprotectin concentration in feces was significantly related to the SCCAI (p = 0.034) and the Mayo endoscopic subscore (p = 0.031). There was a significant association between the C-reactive protein (CRP) value, leucocytes and thrombocytes and the SCCAI, but only leucocytes were significantly associated with the Mayo endoscopic subscore. In Crohn's disease (CD) patients, there was no statistical significant association between the Harvey-Bradshaw Index (HBI) and the endoscopic grade of mucosal inflammation (p = 0.8). The calprotectin concentration in feces was significantly related to the endoscopic activity score (p = 0.004), but not to the HBI (p = 0.5). HBI was significantly related to the CRP value (p = 0.047) and thrombocytes (p = 0.03). CONCLUSIONS: In UC, both biochemical and fecal markers are related to disease activity and extent of disease, whereas in CD, the fecal calprotectin concentration is a reliable marker of mucosal affection, but not for systemic disease activity.


Assuntos
Proteína C-Reativa/metabolismo , Colite Ulcerativa/sangue , Doença de Crohn/sangue , Fezes/química , Complexo Antígeno L1 Leucocitário/análise , Índice de Gravidade de Doença , Adolescente , Adulto , Idoso , Antibacterianos/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Biomarcadores/análise , Biomarcadores/sangue , Colite Ulcerativa/patologia , Doença de Crohn/patologia , Endoscopia Gastrointestinal , Feminino , Humanos , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Noruega , Contagem de Plaquetas , Estudos Prospectivos , Adulto Jovem
10.
Am J Pathol ; 173(4): 1229-42, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18787100

RESUMO

Interleukin (IL)-33 is a novel member of the IL-1 family of cytokines that promotes Th2 responses in lymphocytes as well as the activation of both mast cells and eosinophils via the ST2 receptor. Additionally, IL-33 has been proposed to act as a chromatin-associated transcriptional regulator in both endothelial cells of high endothelial venules and chronically inflamed vessels. Here we show that nuclear IL-33 is expressed in blood vessels of healthy tissues but down-regulated at the earliest onset of angiogenesis during wound healing; in addition, it is almost undetectable in human tumor vessels. Accordingly, IL-33 is induced when cultured endothelial cells reach confluence and stop proliferating but is lost when these cells begin to migrate. However, IL-33 expression was not induced by inhibiting cell cycle progression in subconfluent cultures and was not prevented by antibody-mediated inhibition of VE-cadherin. Conversely, IL-33 knockdown did not induce detectable changes in either expression levels or the cellular distribution of either VE-cadherin or CD31. However, activation of endothelial cell cultures with either tumor necrosis factor-alpha or vascular endothelial growth factor and subcutaneous injection of these cytokines led to a down-regulation of vascular IL-33, a response consistent with both its rapid down-regulation in wound healing and loss in tumor endothelium. In conclusion, we speculate that the proposed transcriptional repressor function of IL-33 may be involved in the control of endothelial cell activation.


Assuntos
Núcleo Celular/metabolismo , Endotélio/metabolismo , Inflamação/metabolismo , Interleucinas/metabolismo , Neovascularização Patológica/metabolismo , Animais , Vasos Sanguíneos/efeitos dos fármacos , Vasos Sanguíneos/metabolismo , Contagem de Células , Movimento Celular/efeitos dos fármacos , Núcleo Celular/efeitos dos fármacos , Células Cultivadas , Citocinas/farmacologia , Regulação para Baixo/efeitos dos fármacos , Endotélio/efeitos dos fármacos , Endotélio/patologia , Feminino , Saúde , Humanos , Interleucina-33 , Neoplasias/metabolismo , Neoplasias/patologia , Ratos , Fator de Necrose Tumoral alfa/farmacologia , Fator A de Crescimento do Endotélio Vascular/farmacologia , Cicatrização/efeitos dos fármacos
11.
J Invest Dermatol ; 135(7): 1771-1780, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25739051

RESUMO

IL-33 is a novel IL-1 family member with a putative role in inflammatory skin disorders and a complex biology. Therefore, recent conflicting data regarding its function in experimental models justify a close assessment of its tissue expression and regulation. Indeed, we report here that there are strong species differences in the expression and regulation of epidermal IL-33. In murine epidermis, IL-33 behaved similar to an alarmin, being constitutively expressed in keratinocyte nuclei and rapidly lost during acute inflammation. By contrast, human and porcine IL-33 were weakly expressed or absent in keratinocytes of noninflamed skin but induced during acute inflammation. To this end, we observed that expression of IL-33 in human keratinocytes but not murine keratinocytes was strongly induced by IFN-γ, and this upregulation completely depended on the presence of EGFR ligands. Accordingly, IFN-γ increased the expression of IL-33 in the basal layers of the epidermis in human ex vivo skin cultures only, despite good evidence of IFN-γ activity in cultures from both species. Together these findings demonstrate that a full understanding of IL-33 function in clinical settings must take species-specific differences into account.


Assuntos
Dermatite/genética , Epiderme/imunologia , Regulação da Expressão Gênica , Inflamação/genética , Interleucinas/genética , Adulto , Animais , Biópsia por Agulha , Western Blotting , Dermatite/fisiopatologia , Modelos Animais de Doenças , Epiderme/metabolismo , Epiderme/patologia , Feminino , Homeostase/genética , Homeostase/fisiologia , Humanos , Imuno-Histoquímica , Inflamação/fisiopatologia , Interleucina-33 , Queratinócitos/imunologia , Queratinócitos/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase em Tempo Real/métodos , Estudos de Amostragem , Especificidade da Espécie , Sus scrofa , Suínos , Técnicas de Cultura de Tecidos
12.
Trends Immunol ; 30(5): 227-33, 2009 May.
Artigo em Inglês | MEDLINE | ID: mdl-19359217

RESUMO

Cytokines are thought to exert biological effects through their specific cell surface membrane receptors but increasing evidence suggests that some also function within the nucleus. Here, we review current knowledge of such cytokines, including the novel interleukin (IL)-1 family member IL-33. Its extracellular function has attracted much recent attention as a ligand for the Th2-associated ST2 receptor, but the discoveries of its nuclear functions and modes of secretion are only just beginning to surface. We review the currently available data on IL-33 regulation, nuclear function and release and discuss them in the context of other intranuclear cytokines and the prototype alarmin HMGB1, considering to what extent IL-33 can be seen as a novel member of the alarmin family.


Assuntos
Interleucinas/fisiologia , Animais , Citocinas/fisiologia , Proteína HMGB1/fisiologia , Humanos , Interleucina-1/fisiologia , Interleucina-33 , Modelos Biológicos , Proteínas Nucleares/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA